The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma

被引：4
|
作者：
Park, Jong Chul [1 ]
Durbeck, Julia [2 ]
Boudadi, Karim [3 ]
Ho, Wen Jin [3 ]
Kang, Hyunseok [4 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Massachusetts Eye & Ear, Boston, MA USA
[3] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Univ Calif San Francisco, 1825 4th St, San Francisco, CA 94158 USA
来源：
ORAL ONCOLOGY | 2020年 / 108卷
关键词：
ANTITUMOR-ACTIVITY;
D O I：
10.1016/j.oraloncology.2020.104935
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer
    Shi, Shuling
    Li, Bingyan
    Zhou, Pengcheng
    Chen, Linhui
    Li, Huizhen
    Wang, Yingyi
    Deng, Xiaoyu
    Dang, Qianqian
    Wu, Jingjing
    Zha, Boya
    Li, Peihong
    Zheng, Yingjuan
    Yang, Daoke
    [J]. CANCER MEDICINE, 2024, 13 (14):
  • [2] Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
    Novotny, J. F., Jr.
    Cogswell, J.
    Inzunza, H.
    Harbison, C.
    Horak, C.
    Averbuch, S.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (10) : 1966 - 1969
  • [3] Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient
    Biondani, P.
    De Martin, E.
    Samuel, D.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (01) : 286 - 287
  • [4] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    Naidoo, J.
    Page, D. B.
    Li, B. T.
    Connell, L. C.
    Schindler, K.
    Lacouture, M. E.
    Postow, M. A.
    Wolchok, J. D.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (12) : 2375 - 2391
  • [5] Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor
    Jing, Xuquan
    Zhu, Hui
    Li, Yuying
    Jia, Wenxiao
    Zhai, Xiaoyang
    Li, Ji
    Yu, Jinming
    [J]. IMMUNOTHERAPY, 2022, 14 (14) : 1097 - 1107
  • [6] Hydroxychloroquine synergizes with anti-PD-1 immune checkpoint blockade in squamous carcinoma of the head and neck
    Vyas, A.
    Cruz-Rangel, S.
    Khan, N.
    Ferris, R.
    Bruno, T.
    Schmitt, N.
    Kiselyov, K.
    Duvvuri, U.
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 174 : S127 - S127
  • [7] Eosinophilic Asthma Secondary to Adjuvant Anti-PD-1 Immune Checkpoint Inhibitor Treatment in a Melanoma Patient
    Kissoonsingh, P.
    Sutton, B.
    Iqbal, Syed U.
    Pallan, Lalit
    Steven, Neil
    Khoja, L.
    [J]. CASE REPORTS IN ONCOLOGICAL MEDICINE, 2022, 2022
  • [8] Anti-PD-1 Immune Checkpoint Inhibitor Therapy Induces Dilated Cardiomyopathy in Tumor Bearing Mice
    Tichy, Louisa
    Parry, Traci L.
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2024, 194 (04): : S16 - S16
  • [9] HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment
    Kim, Young-Dae
    Park, Sang-Min
    Ha, Hae Chan
    Lee, A. Reum
    Won, Heeyoung
    Cha, Hyunju
    Cho, Sangsook
    Cho, Joong Myung
    [J]. JOURNAL OF CANCER, 2020, 11 (14): : 4059 - 4072
  • [10] CS3003, an HDAC6-selective inhibitor, improves anti-PD-1 immune checkpoint blockade therapy efficacy
    Li, Zhenhu
    Ren, Zhaoxiang
    Ma, Jingshu
    Tang, Liang
    Lu, Liang
    Zhu, Ying
    Wu, Yunfei
    Liu, Tiancheng
    Zhang, Juan
    Bao, Yuanwu
    Zhang, Kangyu
    Wei, Changqing
    Chen, Shuhui
    Wang, Xinzhong Jon
    [J]. CANCER RESEARCH, 2020, 80 (16)
12345